为探讨治疗非新生血管性顽固性青光眼的有效方法，对３７例（４６眼）非新生血管性顽固性青光眼，随机分为ＨＡＤ房水引流物置入术组（ＨＡＤ组，２４眼）与小梁切除术联合应用丝裂霉素Ｃ治疗组（ＭＭＣ组，２２只眼），平均随访１５８月（３～３４月）。术后一年眼压峰值（Ｘ±ＳＤ）：ＨＡＤ组为１７０±６４ｍｍＨｇ，ＭＭＣ组为１８７±７５ｍｍＨｇ（Ｐ＜００５）；眼压下降率（Ｘ±ＳＤ）：ＨＡＤ组为６３５％±１７９％，ＭＭＣ组为４９６％±１７４％（Ｐ＜００５）。手术成功率：术后一年ＨＡＤ组为９００％，ＭＭＣ组为８２４％（Ｐ＞００５）；术后一年半时，ＨＡＤ组为８８９％，ＭＭＣ组为７００％（Ｐ＞００５）；术后两年时，ＨＡＤ组为８３３％，ＭＭＣ组为５７１％（Ｐ＞００５）。术后并发症，ＭＭＣ组前房积血（３６４％）多见（Ｐ＜００１），此外还可见到低眼压性黄斑病变（４５％）等并发症；ＨＡＤ组亦有引流管前房端纤维膜闭（１６７％），引流管与其周围虹膜粘连（８３％）等并发症。结果：本组病例行ＨＡＤ房水引流物置入术的手术成功率与国外同类产品相似。在常规滤过性手术联合应用抗瘢痕形成药物治疗顽固性青光眼失败? In order to explore an effective method for the treatment of non-neovascular refractory glaucoma, 37 patients (46 eyes) with non-neovascular refractory glaucoma were randomly divided into three groups: HAD group (24 eyes) and trabecular meshwork Resection combined with mitomycin C treatment group (MMC group, 22 eyes), the average follow-up 15  August (3 to 34 months). One year after operation, the intraocular pressure (X ± SD) was 170 ± 64 mmHg in HAD group and 187 ± 75 mmHg in MMC group (P <005) ) Were 635 ± 179% in HAD group and 496 ± 174% in MMC group (P <005). The successful rate of surgery was 900% in HAD group and 824% in MMC group (P> 0.05). One year and a half after operation, HAD group was 889% and MMC group was 70  0% (P> 005). Two years after operation, HAD group was 833% and MMC group was 571% (P> 005). Postoperative complications were more common in the MMC group (36.4%) than in the MMC group (P <001), and complications such as low-ocular macular degeneration (4.5%) were also observed. In the HAD group A drainage tube anterior chamber fibrous membrane closure (16.7%), the drainage tube and the surrounding iris adhesions (8.3%) and other complications. Results: The success rate of HAD aqueous humor implantation in this group was similar to that of similar foreign products. In conventional filtering surgery combined with anti-scarring drug treatment of refractory glaucoma failed?